Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...
Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...
Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
Metabolic reprogramming in the tumor microenvironment shapes immune function and therapy resistance, offering insights into ...
Immune checkpoint inhibitors have significantly improved survival for a variety of malignancies over the past decade, but the costs of these medications have barely changed.An investigation into 11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback